Immunodeficiency in protein kinase Cβ-deficient mice

Science

Volumn 273, Issue 5276, 1996, Pages 788-791

  Leitges, Michael ^a,d   Schmedt, Christian ^b   Guinamard, Rodolphe ^c   Davoust, Jean ^c   Schaal, Stefan ^b   Stabel, Silvia ^a   Tarakhovsky, Alexander ^b  

^a Max Delbruck Laboratorium der Max Planck Gesellschaft   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c INSERM   (France)

^d MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVATION; ENZYME DEFICIENCY; GENE DISRUPTION; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA;

ANIMALIA;

EID: 0029739626     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5276.788     Document Type: Article

References (57)

1. E. Baixeras et al., Immunol. Rev. 132, 5 (1993); A. Weiss and D. R. Littman, Cell 76, 263 (1994).
2. E. Baixeras et al., Immunol. Rev. 132, 5 (1993); A. Weiss and D. R. Littman, Cell 76, 263 (1994).
3. Y. Nishizuka. Science 258, 607 (1992); H. Hug and T. F. Sarre, Biochem. J. 291, 329 (1993); L. V. Dekker and P. J. Parker, Trends Biochem. Sci. 19. 73 (1994); S, Stabel, Semin. Cancer Biol. 5, 277 (1994); Y. Nishizuka, FASEB J. 9, 484 (1995).
4. Y. Nishizuka. Science 258, 607 (1992); H. Hug and T. F. Sarre, Biochem. J. 291, 329 (1993); L. V. Dekker and P. J. Parker, Trends Biochem. Sci. 19. 73 (1994); S, Stabel, Semin. Cancer Biol. 5, 277 (1994); Y. Nishizuka, FASEB J. 9, 484 (1995).
5. Y. Nishizuka. Science 258, 607 (1992); H. Hug and T. F. Sarre, Biochem. J. 291, 329 (1993); L. V. Dekker and P. J. Parker, Trends Biochem. Sci. 19. 73 (1994); S, Stabel, Semin. Cancer Biol. 5, 277 (1994); Y. Nishizuka, FASEB J. 9, 484 (1995).
6. Y. Nishizuka. Science 258, 607 (1992); H. Hug and T. F. Sarre, Biochem. J. 291, 329 (1993); L. V. Dekker and P. J. Parker, Trends Biochem. Sci. 19. 73 (1994); S, Stabel, Semin. Cancer Biol. 5, 277 (1994); Y. Nishizuka, FASEB J. 9, 484 (1995).
7. Y. Nishizuka. Science 258, 607 (1992); H. Hug and T. F. Sarre, Biochem. J. 291, 329 (1993); L. V. Dekker and P. J. Parker, Trends Biochem. Sci. 19. 73 (1994); S, Stabel, Semin. Cancer Biol. 5, 277 (1994); Y. Nishizuka, FASEB J. 9, 484 (1995).
8. J. C. Cambier et al., Nature 327. 629 (1987); D. T. Francois et al., J. Immunol. 140, 3338 (1988); G. A. Koretzky, M. Wahi, M. E. Newton, A. Weiss, ibid. 143, 1692 (1989); J. Freire-Moar, H. Cherwinski, F. Hwang, J. Ransom, D. Webb, ibid. 147, 405 (1991); M. Szamel and K. Resch, Eur. J. Biochem. 228, 1 (1995).
9. J. C. Cambier et al., Nature 327. 629 (1987); D. T. Francois et al., J. Immunol. 140, 3338 (1988); G. A. Koretzky, M. Wahi, M. E. Newton, A. Weiss, ibid. 143, 1692 (1989); J. Freire-Moar, H. Cherwinski, F. Hwang, J. Ransom, D. Webb, ibid. 147, 405 (1991); M. Szamel and K. Resch, Eur. J. Biochem. 228, 1 (1995).
10. J. C. Cambier et al., Nature 327. 629 (1987); D. T. Francois et al., J. Immunol. 140, 3338 (1988); G. A. Koretzky, M. Wahi, M. E. Newton, A. Weiss, ibid. 143, 1692 (1989); J. Freire-Moar, H. Cherwinski, F. Hwang, J. Ransom, D. Webb, ibid. 147, 405 (1991); M. Szamel and K. Resch, Eur. J. Biochem. 228, 1 (1995).
11. J. C. Cambier et al., Nature 327. 629 (1987); D. T. Francois et al., J. Immunol. 140, 3338 (1988); G. A. Koretzky, M. Wahi, M. E. Newton, A. Weiss, ibid. 143, 1692 (1989); J. Freire-Moar, H. Cherwinski, F. Hwang, J. Ransom, D. Webb, ibid. 147, 405 (1991); M. Szamel and K. Resch, Eur. J. Biochem. 228, 1 (1995).
12. J. C. Cambier et al., Nature 327. 629 (1987); D. T. Francois et al., J. Immunol. 140, 3338 (1988); G. A. Koretzky, M. Wahi, M. E. Newton, A. Weiss, ibid. 143, 1692 (1989); J. Freire-Moar, H. Cherwinski, F. Hwang, J. Ransom, D. Webb, ibid. 147, 405 (1991); M. Szamel and K. Resch, Eur. J. Biochem. 228, 1 (1995).
13. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
14. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
15. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
16. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
17. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
18. L. Coussens et al., Science 233, 859 (1986); Y. Ono et al., ibid. 236, 1116 (1987); H. Mischak et al., J. Immunol. 147, 3981 (1991); D. P. Cohen and T. L. Rothstein, ibid. 146, 2921 (1991); D. Kelleher and A. Long, FEBS Left. 301, 310 (1992); N. Tarantino, P. Debre, M. Korner, ibid. 338, 339 (1994).
19. The lacZ-neo cassette was inserted into the second exon of the PKC-β gene by homologous recombination. Details of the cloning and mapping of the PKC-β gene, electroporation of ES cells, selection of recombinants, generation of chimeric mice, and the analysis of expression of the PKC-β-β-galactosidase fusion protein in various tissues are described elsewhere (M. Leitges et al., in preparation). Mice heterozygous for the disruption of the PKC-β gene were backcrossed to 129/Sv mice, and F, mice were bred to generate PKC-β / mice on a pure 129/Sv genetic background. For the analysis of PKC-β protein spleens or thymuses of mice were disrupted on ice with a Dounce homogenizer in 50 mM tris-HCI (pH 7.5), 2 mM EDTA (pH 7.0), 10 mM EGTA (pH 7.0), 0.1% Triton X-100, 0.3% β-mercaptoethanol, phenylmethylsulfonyl fluoride (PMSF) (50 μg/ml), leupeptin (20 μg/ml), and aprotinin (20 μg/ml). After centrifugation for 20 min at 15000g, soluble proteins were separated on a 8.5% SDS-polyacrylamide gel and blotted onto nitrocellulose, and PKC-β protein was identified with PKC-β-specific antibodies (25) with the use of ECL reagents (Amersham).
20. +) single-positive cells in peripheral lymphoid organs and thy mocytes were counted as described (26).
21. R. R. Hardy and K. Hayakawa, Adv. Immunol. 55, 297 (1994); T. J. Kipps, ibid. 47, 117 (1989).
22. R. R. Hardy and K. Hayakawa, Adv. Immunol. 55, 297 (1994); T. J. Kipps, ibid. 47, 117 (1989).
23. L. A. Herzenberg et al., Immunol. Rev. 93, 81 (1986); I. Förster and K. Rajewsky, Eur. J. Immunol. 17, 521 (1987)
24. L. A. Herzenberg et al., Immunol. Rev. 93, 81 (1986); I. Förster and K. Rajewsky, Eur. J. Immunol. 17, 521 (1987)
25. Mice were bled from the tail vein, and the serum concentrations of different isotypes were determined by enzyme-linked immunosorbent assay (ELISA) as described (26). Data were evaluated by t test, with the use of Statistica software.
26. D. F. Amsbaugh et al., J. Exp. Med. 136, 931 (1972); I. Scher, A. K. Berning, R. Asofsky, J. Immunol. 123, 477 (1979); I. Scher, Adv. Immunol. 33. 1 (1982).
27. D. F. Amsbaugh et al., J. Exp. Med. 136, 931 (1972); I. Scher, A. K. Berning, R. Asofsky, J. Immunol. 123, 477 (1979); I. Scher, Adv. Immunol. 33. 1 (1982).
28. D. F. Amsbaugh et al., J. Exp. Med. 136, 931 (1972); I. Scher, A. K. Berning, R. Asofsky, J. Immunol. 123, 477 (1979); I. Scher, Adv. Immunol. 33. 1 (1982).
29. J. D. Thomas et al., Science 261. 355 (1993); D. J. Rawlings et al., ibid., p. 358.
30. J. D. Thomas et al., Science 261. 355 (1993); D. J. Rawlings et al., ibid., p. 358.
31. C. I. Smith et al., Immunol. Rev. 138, 159 (1994); I. Vorechovsky et al., Hum. Mol. Genet. 4, 51 (1995).
32. C. I. Smith et al., Immunol. Rev. 138, 159 (1994); I. Vorechovsky et al., Hum. Mol. Genet. 4, 51 (1995).
33. W. N. Khan et al., Immunity 3, 283 (1995); J. D. Kerner et al., ibid., p. 301.
34. W. N. Khan et al., Immunity 3, 283 (1995); J. D. Kerner et al., ibid., p. 301.
35. M. de Weers et al., Eur. J. Immunol. 23, 3109 (1993); S. J. Saouaf et al., Proc. Nati. Acad. Sci. U.S.A. 91, 9524 (1994); C. I. Smith et al., J. Immunol. 152, 557 (1994); Y. Aoki, K. J. Isselbacher, S. Pillai, Proc. Natl. Acad. Sci. U.S.A. 91, 10606 (1994).
36. M. de Weers et al., Eur. J. Immunol. 23, 3109 (1993); S. J. Saouaf et al., Proc. Nati. Acad. Sci. U.S.A. 91, 9524 (1994); C. I. Smith et al., J. Immunol. 152, 557 (1994); Y. Aoki, K. J. Isselbacher, S. Pillai, Proc. Natl. Acad. Sci. U.S.A. 91, 10606 (1994).
37. M. de Weers et al., Eur. J. Immunol. 23, 3109 (1993); S. J. Saouaf et al., Proc. Nati. Acad. Sci. U.S.A. 91, 9524 (1994); C. I. Smith et al., J. Immunol. 152, 557 (1994); Y. Aoki, K. J. Isselbacher, S. Pillai, Proc. Natl. Acad. Sci. U.S.A. 91, 10606 (1994).
38. M. de Weers et al., Eur. J. Immunol. 23, 3109 (1993); S. J. Saouaf et al., Proc. Nati. Acad. Sci. U.S.A. 91, 9524 (1994); C. I. Smith et al., J. Immunol. 152, 557 (1994); Y. Aoki, K. J. Isselbacher, S. Pillai, Proc. Natl. Acad. Sci. U.S.A. 91, 10606 (1994).
39. J. Hasbold and G. G. Klaus, Eur. J. Immunol. 24, 152 (1994); S. Sato et al., J. Exp. Med. 180, 2101 (1994); L. Santos-Argumedo et al., Int. Immunol. 7, 163 (1995)
40. J. Hasbold and G. G. Klaus, Eur. J. Immunol. 24, 152 (1994); S. Sato et al., J. Exp. Med. 180, 2101 (1994); L. Santos-Argumedo et al., Int. Immunol. 7, 163 (1995)
41. J. Hasbold and G. G. Klaus, Eur. J. Immunol. 24, 152 (1994); S. Sato et al., J. Exp. Med. 180, 2101 (1994); L. Santos-Argumedo et al., Int. Immunol. 7, 163 (1995)
42. R. M. Perlmutter et al., J. Exp. Med. 149, 993 (1979); K. Haykawa, R. R. Hardy, L. A. Herzenberg, Eur. J. Immunol. 16, 450 (1986).
43. R. M. Perlmutter et al., J. Exp. Med. 149, 993 (1979); K. Haykawa, R. R. Hardy, L. A. Herzenberg, Eur. J. Immunol. 16, 450 (1986).
44. J. J. Mond, Q. Vos, A. Lees, C. M. Snapper, Curr. Opin. Immunol. 7, 349 (1995).
45. 16-CG in PBS on day 50 after the primary immunization. The serum concentrations of NP- and CG-specific antibodies were determined at different times after immunization as described (27).
46. B. Huber and F. Melchers. Eur. J. Immunol. 9, 827 (1979); J. J. Mond, M. Schaefer, J. Smith, F. D. Finkelman, J. Immunol. 131, 2107 (1983); K. P. Rigley, M. M. Harnett, R. J. Phillips, G. G, Klaus, Eur. J. Immunol. 19, 2081 (1989).
47. B. Huber and F. Melchers. Eur. J. Immunol. 9, 827 (1979); J. J. Mond, M. Schaefer, J. Smith, F. D. Finkelman, J. Immunol. 131, 2107 (1983); K. P. Rigley, M. M. Harnett, R. J. Phillips, G. G, Klaus, Eur. J. Immunol. 19, 2081 (1989).
48. B. Huber and F. Melchers. Eur. J. Immunol. 9, 827 (1979); J. J. Mond, M. Schaefer, J. Smith, F. D. Finkelman, J. Immunol. 131, 2107 (1983); K. P. Rigley, M. M. Harnett, R. J. Phillips, G. G, Klaus, Eur. J. Immunol. 19, 2081 (1989).
49. 2 fragment goat anti-mouse IgM (2.5 μG/ml) (Dianova, Germany) as described (26). Data were evaluated by t test, with the use of Statistica software.
50. G. G. Klaus and M. M. Harnett, Eur. J. Immunol. 20, 2301 (1990).
51. 2 goat antimouse IgM (25 μg/ml) at 37°C and the reaction was stopped at different times by placement of cells on ice. Cells were lysed for 20 min at 4°C in lysis buffer containing 1% NP-40; 20 mM triethanolamine (pH 7.8); 150 mM NaCl; 500 mM EDTA; 100 mM orthovanadate; and a mixture of protease inhibitors-PMSF, pepstatin, leupeptin, and antipain at standard concentrations (5, 26). For the analysis of Btk phosphorylation. Btk was precipitated from cell lysates with a rabbit polyclonal antiserum raised against a peptide corresponding to amino acids 71 to 93 of Btk. The specificity of the immunoprecipitation was controlled by incubation of cell lysates with the antiserum to Btk in the presence of the immunogenic peptide for 1 hour. The phosphorylation of Btk was determined by protein immunoblot analysis of immunoprecipitates with the antibody to phosphotyrosine 4G10 and was detected with ECL reagents (Amersham). All samples contained equal amount of immunoreactive protein as determined by immunoblot analysis of immunoprecipitates with antibodies to Btk.
52. L. Yao, Y. Kawakami, T. Kawakami, Proc. Natl. Acad. Sci U.S.A. 91, 9175 (1994).
53. M. L. Lindsberg et al., J. Immunol. 147, 3774 (1991).
54. R. M. Marais and P. J. Parker, Eur. J. Biochem. 182, 129 (1989).
55. A. Tarakhovsky et al., Nature 374, 467 (1995).
56. R. R. Rickert, K. Rajewsky, J. Roes, ibid. 376, 352 (1995).
57. We thank A. Benner, C. Uthoff-Hachenberg, and C. Göttlinger for technical assistance; P. Parker for the antibodies to PKC-βll; R. Kühn for E14.1 ES cells; K. Rajewsky for support and helpful discussions; and R. Pelanda, R. Rickert, R. Torres, and N. Wagner for critical reading of the manuscript. Supported by the Bundesministerium für Forschung und Technologie (BMFT grant 0316150A) (S.St.), the Deutsche Forschungsgemeinschaft through Sonderforschungsbereich 243 (A.T.), and the Fonds der Chemischen Industrie (C.S.).